6th Middle East Pharmacoeconomics and Drug Policy Summit (2026)

  • Address: Crowne Plaza RDC - Riyadh, Saudi Arabia (Map)
  • Tel: Show Number
  • Date: Sat, Apr 18, 2026 – Sun, Apr 19, 2026 ( Add to Calendar 04/18/2026 04/19/2026 6th Middle East Pharmacoeconomics and Drug Policy Summit (2026) HTA Ignite: Real-World, Real-Impact The ME Pharmacoeconomics & Drug Policy Summit, under the core theme “HTA Ignite: Real-World,Real-Impact,” highlights evidence-based assessments and the development of transparent frameworksfor value-driven healthcare decisions across the Middle East. The event will gather regulators, healtheconomists, payers, providers, and industry leaders to share insights, exchange strategies, and explore innovative approaches for enhancing patient outcomes while maximizing resource efficiency. The summit will demonstrate how Health Technology Assessment (HTA) harnesses Real-World Data (RWD) to produce actionable Real-World Evidence (RWE) by assessing the clinical, economic, and societal impact of therapies, HTA enables value-based pricing, improves access to advanced treatments, and promotes sustainable healthcare practices. Integrating RWE with HTA ensures that policies are both practical and patient-centered, driving long-term improvements in healthcare delivery across the region.

    Who Should Attend

    • Regulatory Authorities
    • Pharmacoeconomists
    • Health Economists
    • Health Technology Assessment Specialists
    • Payers & Health Insurance – Drug Pricing & Reimbursement Departments
    • Healthcare Providers
    • Pharma Industry: Market Access Teams
    • Pharmacists
    • Real-World Evidence (rwe) and Real-World Data (rwd) Experts
    • Heor (health Economics & Outcomes Research) Professionals
    • Pricing and Policy Strategists
    • National Hta Agencies and Committees

    Key Benefits of Attending

    • Highlight Future Opportunities and Challenges in Developing the Healthcare and Research Economy in The Gcc Countries
    • Discuss the Novel Approaches to Value Assessment, Achieving Cost Effective Healthcare Solutions and Access to Innovative Medicines in The Gcc
    • Understanding the Principles of Outcome Based Healthcare and Evidence Based Medication
    • Reviewing Pharmacoeconomics and Outcomes Research Strategies
    • Exploring the real world data, the burden of disease and HTA to make proper assessments and support decision making
    )

Event Inquiry

HTA Ignite: Real-World, Real-Impact

The ME Pharmacoeconomics & Drug Policy Summit, under the core theme “HTA Ignite: Real-World,Real-Impact,” highlights evidence-based assessments and the development of transparent frameworksfor value-driven healthcare decisions across the Middle East. The event will gather regulators, healtheconomists, payers, providers, and industry leaders to share insights, exchange strategies, and explore innovative approaches for enhancing patient outcomes while maximizing resource efficiency.

The summit will demonstrate how Health Technology Assessment (HTA) harnesses Real-World Data (RWD) to produce actionable Real-World Evidence (RWE) by assessing the clinical, economic, and societal impact of therapies, HTA enables value-based pricing, improves access to advanced treatments, and promotes sustainable healthcare practices. Integrating RWE with HTA ensures that policies are both practical and patient-centered, driving long-term improvements in healthcare delivery across the region.

Who Should Attend

  • Regulatory Authorities
  • Pharmacoeconomists
  • Health Economists
  • Health Technology Assessment Specialists
  • Payers & Health Insurance – Drug Pricing & Reimbursement Departments
  • Healthcare Providers
  • Pharma Industry: Market Access Teams
  • Pharmacists
  • Real-World Evidence (rwe) and Real-World Data (rwd) Experts
  • Heor (health Economics & Outcomes Research) Professionals
  • Pricing and Policy Strategists
  • National Hta Agencies and Committees

Key Benefits of Attending

  • Highlight Future Opportunities and Challenges in Developing the Healthcare and Research Economy in The Gcc Countries
  • Discuss the Novel Approaches to Value Assessment, Achieving Cost Effective Healthcare Solutions and Access to Innovative Medicines in The Gcc
  • Understanding the Principles of Outcome Based Healthcare and Evidence Based Medication
  • Reviewing Pharmacoeconomics and Outcomes Research Strategies
  • Exploring the real world data, the burden of disease and HTA to make proper assessments and support decision making